- Sleep apnoea leader continues to set industry standards for CPAP mask comfort and effectiveness, as well as digital health tools to support patients and clinicians
- 8 ResMed sleep products have received Good Design awards in the past 4 years
SYDNEY, 8 September 2020 – Two ResMed CPAP masks today received Good Design Australia Awards in the Product Design category, the AirFit N30 and AirFit F30i, for achieving the highest level of design and innovation in service to patients with sleep apnoea worldwide.
Both masks are designed for maximum comfort, effectiveness, and ease of use. AirFit N30 is the world’s first tube-down nasal cradle CPAP mask, and ResMed’s lightest mask to date. AirFit F30i is ResMed’s first tube-up full face CPAP mask, rounding out the world’s most complete full-face mask portfolio that features compact and traditional cushions, plus a memory foam cushion for unique comfort.
“At ResMed, we believe there’s a CPAP mask for every patient to get a healthy night’s sleep and awaken their best,” said Mark Buckley, ResMed’s vice president of sleep product development. “We’re honored that Good Design Australia has recognized AirFit N30 and F30i as two more great options, and glad that so many patients and clinicians worldwide have chosen them as well.”
ResMed sleep apnoea products now has eight Good Design Awards. Other winners include:
- AirFit N30i, tube-up nasal mask (2019)
- AirFit P30i, tube-up nasal pillows mask (2019)
- AirFit N20, nasal mask that fits 99% of wearers (2017)
- AirFit F20, full face mask that fits 97% of wearers (2017)
- AirTouch F20, ResMed’s softest full face mask, with UltraSoft memory foam cushion (2017)
- AirMini, still the world’s smallest CPAP, featuring waterless humidification and smartphone operation (2017)
ResMed invests 7–8 percent of its annual revenue (US$3 billion annual revenue in fiscal year 2020) back into research and development of the next innovations in sleep and respiratory care devices, plus digital health solutions that support patients and healthcare professionals.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
# # #
MEDIA CONTACT: Jayme Rubenstein, +1 858.836.6798, [email protected]